University of Michigan to receive $2.38M to test tumor cell-killing drug
ANN ARBOR, MI–A new medicine out of the University of Michigan uses a protein that can carry a tumor cell-killing drug to fight brain cancer. Now the school will receive $2.38 million from the National Institutes of Health to test the technology. The research will be led by a nano-engineer and neuro-oncology researchers at UM, and is the first study to test the two drugs together in a way that can be delivered through the bloodstream rather than a hole in the skull.
South Korean immunotherapy developer expands to Indiana
FISHERS, IN–South Korean immunotherapy developer List Biotherapeutics will build a new $125 million microbiome facility in Fishers, Indiana at the Fishers Life Science & Innovation Park as part of the company’s objective to expand its CMO business. The Fishers Life Science & Innovation Park was established in August 2021 and has seen more than $200 million in investment from life science firms Stevanato Group and INCOG Pharma, with just eight acres remaining for development.
Nashville health data company acquired
NASHVILLE, TN–Healthcare market intelligence company Stratasan will be acquired by Chicago-based Syntellis Performance Solutions. Syntellis is adding Stratasan to its suite of intelligent planning software offerings, with the goal of helping healthcare organizations determine where, when and how to grow.
$14.2M to Cleveland Clinic for atrial fibrillation research
CLEVELAND, OH–Cleveland Clinic has been awarded a $14.2 million grant from the National Institutes of Health for atrial fibrillation research. The five-year award will support four synergistic projects aimed at improving and finding new treatments for patients with atrial fibrillation, the most common heart rhythm abnormality.
Special Purpose Vehicle investing model targets healthcare
MINNEAPOLIS, MN–VC firm Engage Venture Partners invests in the medical device healthtech and health SaaS categories using a special purpose model (SPV). An SPV treats each investment as its own fund (a ‘fund of one’), rather than investing into a blind pool that makes investments over a number of years, which allows investors to invest in individual companies. That discretion allows investors to focus their capital on their own special interests.